Qualys issued an update on the security incident regarding the Accellion FTA file transfer solution. "Qualys received new information about a previously identified zero-day exploit in a third-party solution, Accellion FTA that Qualys deployed to transfer files as part of our customer support system," the company said. "Qualys confirms today there is no impact on the Qualys production environments, codebase or customer data hosted on the Qualys Cloud Platform. All Qualys platforms continue to be fully functional and at no time was there any operational impact. Qualys had deployed the Accellion FTA server in a segregated DMZ environment, completely separate from systems that host and support Qualys products to transfer information as part of our customer support system. Qualys chose the Accellion FTA solution for encrypted temporary transfer of manually uploaded files. There was no connectivity between the Accellion FTA server and our production customer data environment (the Qualys Cloud Platform). The Accellion FTA product is a third-party system fully managed by Accellion. As with any security incident, the investigation is ongoing, and we continue to look for ways to enhance security and provide the strongest protections for our customers. We have engaged FireEye Mandiant, who also worked with Accellion on the wider investigation. Qualys is strongly committed to the security of its customers and their data, and we will notify them should material information become available."

In an interview on CNBC's Mad Money, Todd Penegor said the company's breakfast business is doing "quite well" with strong repeat customers. Wendy's is seeing a lot more mobile ordering and the loyalty program will help drive the digital mix, he added. Currently, 90% of the business is going through the drive through lanes. When dining rooms open, pressure on the drive through should subside, Penegor noted.

In a regulatory filing, Kiniksa stated: "In September 2017, Kiniksa entered into a License Agreement with Regeneron Pharmaceuticals (REGN), pursuant to which Regeneron granted the company an exclusive license under certain intellectual property rights controlled by Regeneron to develop and commercialize rilonacept for the Kiniksa field and within the territory described therein. Pursuant to an Asset Transfer Agreement between the company and Kiniksa Pharmaceuticals Ltd., a wholly-owned subsidiary of the company, the company assigned the License Agreement to Kiniksa UK in January 2021. In accordance with the License Agreement, Kiniksa UK entered into a Commercial Supply Agreement with Regeneron on March 1, 2021, pursuant to which Regeneron has the exclusive right to manufacture and supply rilonacept for Kiniksa UK's requirements, which Kiniksa UK may use for its clinical development and commercialization activities. The purchase price and payment terms in the Supply Agreement are in accordance with the terms set forth in the License Agreement."

In a regulatory filing, Azek CEO and president Jesse G. Singh disclosed the sale of 55,000 class A common shares of the company on March 1 at a price of $44.86 per share.